Biographies

James C. Mulloy, PhD

Professor, UC Department of Pediatrics

Phone: 513-636-1844

Fax: 513-636-3768

Email: james.mulloy@cchmc.org

Show All

Specialties

Education and Training

BA: St. Anselm College, Manchester, New Hampshire, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1992.

Publications

View PubMed Publications

Grants

Pediatric Biphenotypic Leukemia. Co-Principal Investigator. Cincinnati Children’s – Sheba Medical Center (Israeli/Mulloy). Nov 2013-Oct 2014.

Conferring in vivo metabolic resistance to a highly selective anti-AML agent. Co-Investigator. National Institutes of Health R21 NCI (Merino/Mulloy). Apr 2014-Mar 2016.

Origin and progression of Myelosdysplastic syndrome in patients with Bone Marrow Failure Disorders. Co-Investigator. Center for Clinical and Translational Science and Training (Mehta/Mulloy/Cancelas). Jul 2014-Jun 2015.

Therapeutic Targeting of LARG-RhoA signaling in childhood leukemia. Co-Principal Investigator. Alex's Lemonade Stand (Zheng/Mulloy). July 2013-June 2015.

SGN-CD33A anti-tumor activity against relapse AML. Seattle Genetics.  June 2013-May 2014.

Targeting Cdc42 in leukemia stem cells. Co-Principal Investigator. National Cancer Institute. Apr 2010-Mar 2015. #1R01CA150547-01. 

Rac Signaling in MLL Leukemia. Principal Investigator. Leukemia and Lymphoma Society. Jul 2010-Jun 2015.

Cincinnati Center of Excellence in Molecular Hematology. Co-Director, Animal Core. National Institutes of Health. Sep 2010 – Jul 2015. # P30 DK090971.

Genotype and phenotype of chemoresistant AML. Principal Investigator. NIH, NCI. Mar 13-Feb 15. R21 CA168369

Hemostatic system components as novel therapeutic targets in childhood AML. Co-Principal Investigator. Center for Clinical and Translational Science and Training (Palumbo/Mulloy). Jul 13-Jun 14.

A Novel ROS-activated Therapeutic Modality for AML. Co-Principal Investigator. Center for Clinical and Translational Science and Training (Merino/Mulloy). Jul 13-Jun 14.

Validation and structural requirements of a novel anti-leukemia agent. Co-Principal Investigator. UC Technology Commercialization Accelerator (Merino/Mulloy). University of Cincinnati. Apr 13-Mar 14  

Efficacy and selectivity in combination of novel ROS activated anticancer agent. Co-Principal Investigator. University Research Council-UC (Merino/Mulloy). Interdisciplinary Faculty Research Support Grant. Apr 13-Mar 14

Human IFN- Neutralization in Humanized NSGS Mice Developing Cytopenias. Principal Investigator. NovImmune (Mulloy/Jordan). Mar 13-Feb 14.

LSC mobilization and differentiation therapy. Co-Principal Investigator. Hyundai Hope On Wheels! (Mulloy/Mizukawa). Sep 13-Aug 15.